Pharma Times has reported that the government has established Genomics England, tasked with mapping NHS patients’ DNA to improve genetics research.
The group will manage contract for UK based companies, universities and hospitals involved in supplying DNA sequencing related services. A £100 million initial backing of the company will lead to the training of a “new generation” of genetic scientists to develop pioneering drug treatment breakthroughs.
The programme is subject to consent and all data collected will be anonymous or under pseudonyms, rather than identifiable to specific patients. It is hoped that Genomics England will initially lead to breakthroughs in analysis of lung and children’s cancers, as well as rare and infectious diseases, all of which have been prioritised.